Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04207840 · ClinicalTrials.gov registry record · Phase 4
Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular Injection and ProAir by Oral Inhalation in Healthy Individuals
A Phase 4 study of Asthma and Pharmacokinetics, sponsored by Amphastar Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT04207840 is a Phase 4 study of Asthma and Pharmacokinetics that has completed, run by Amphastar Pharmaceuticals. The registered enrollment target is 28 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04207840, a Phase 4 study of Asthma and Pharmacokinetics, has completed, sponsored by Amphastar Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess the drug exposure profile in systemic circulation of Primatene Mist by inhalation, versus Epinephrine by intramuscular injection, and ProAir HFA by inhalation in healthy adults.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Epinephrine (0.125 mg/inhalation)
- COMBINATION_PRODUCT Epinephrine Injection Auto-Injector (0.3mg/0.3mL)
- COMBINATION_PRODUCT Albuterol Sulfate (0.09 mg/inhalation)
Study Locations (1)
California
- Amphastar Study Site 0035 - Cypress
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2019-12-09 |
| Est. Completion | 2019-12-23 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04207840
The ClinicalTrials.gov registry entry for NCT04207840 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (98% lower). The listed sponsor is Amphastar Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Asthma appearing as the primary indexed condition, and to 3 interventions - of which Epinephrine (0.125 mg/inhalation) is the first listed.
NCT04207840 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04207840 about?
NCT04207840 is a clinical study titled "Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular Injection and ProAir by Oral Inhalation in Healthy Individuals". To assess the drug exposure profile in systemic circulation of Primatene Mist by inhalation, versus Epinephrine by intramuscular injection, and ProAir HFA by inhalation in healthy adults.
What is the current status of trial NCT04207840?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 28 participants. The study started on 2019-12-09. Estimated completion is 2019-12-23.
What conditions does trial NCT04207840 study?
This clinical trial studies the following conditions: Asthma, Pharmacokinetics, Anaphylaxis, Epinephrine, Albuterol.
What interventions are being tested in trial NCT04207840?
The interventions under investigation include: Epinephrine (0.125 mg/inhalation) (COMBINATION_PRODUCT), Epinephrine Injection Auto-Injector (0.3mg/0.3mL) (COMBINATION_PRODUCT), Albuterol Sulfate (0.09 mg/inhalation) (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04207840?
This trial is sponsored by Amphastar Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04207840 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
-
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 4
-
Viral Infection in Asthma (VIA) Study
RECRUITING · Phase 4
-
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
RECRUITING · Phase 4
-
The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)
RECRUITING · Phase 4
-
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.